Biotechnology Company
Appears in 6 stories
mCOMBRIAX approved in EU (April 2026); mRNA-1010 awaiting FDA decision by August 5, 2026
For 80 years, flu vaccines grew in chicken eggs — a process effective against roughly 40% of infections in good years. On May 8, the New England Journal of Medicine published Moderna's Phase 3 data: mRNA-1010 reduced influenza illness by 26.6% more than a standard shot in 40,805 adults aged 50 and older. Moderna's stock rose 16% that day.
Updated May 31
Settled; appealing government-contractor defense to Federal Circuit
For four years, Moderna faced questions about whether it owed billions for technology at the heart of its COVID-19 vaccine. Less than a week before a jury trial in Delaware, Moderna agreed to pay $2.25 billion to settle patent claims from Arbutus Biopharma and Genevant Sciences. The court found it infringed four valid patents, and if paid in full, it would be the largest disclosed patent settlement in pharmaceutical history, surpassing a $2.15 billion Pfizer-Takeda settlement in 2013.
Updated May 30
Developing mRNA-based norovirus vaccine (Phase 3)
Human norovirus eluded laboratory cultivation for nearly six decades, which prevented vaccine development for a pathogen that sickens 700 million people annually. Baylor College of Medicine researchers broke this barrier using the drug TAK-779 to achieve 10 to 15 consecutive rounds of viral replication in lab-grown human intestinal tissue, yielding stable virus stocks for the first time.
Updated May 27
Phase 3 trials for mRNA cancer vaccines
Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely—all remain alive today. Researchers discovered these survivors still carry specialized immune cells capable of recognizing their cancer—evidence of a mechanism that could make therapeutic cancer vaccines work reliably.
Updated May 23
Co-developer of mRNA-4157/V940 cancer vaccine
Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit until now.
Updated May 22
Providing mRNA platform and manufacturing for G004 trial
In 1984, the U.S. Health Secretary predicted an HIV vaccine within two years. After four decades and dozens of failed trials, IAVI is dosing participants in South Africa with a vaccine that trains the immune system from the ground up rather than simply presenting viral proteins.
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
